Abstract
In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
This is a preview of subscription content, log in via an institution to check access.
References
Vannucchi, A. M. et al. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J. Clin. 59, 171–191 (2009).
Quintás-Cardama, A. et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Rev. Drug Discov. 10, 127–140 (2011).
Quintás-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109–3117 (2010).
US Food and Drug Administration. FDA labeling information — Jakafi. FDA website [online], (2011).
Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117–1127 (2010).
Silver, R. T. et al. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117, 6669–6672 (2011).
Mesa, R. A. et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) Phase 2 trial E4903. Blood 116, 4436–4438 (2010).
Cervantes, F. et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br. J. Haematol. 129, 771–775 (2005).
Thepot, S. et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116, 3735–3742 (2010).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information Figure S1
First-line therapy of myelofibrosis in 2012. (PDF 702 kb)
Rights and permissions
About this article
Cite this article
Mesa, R., Yasothan, U. & Kirkpatrick, P. Ruxolitinib. Nat Rev Drug Discov 11, 103–104 (2012). https://doi.org/10.1038/nrd3652
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3652
- Springer Nature Limited
This article is cited by
-
Design, synthesis, and antiproliferative activities of novel thiazolyl-pyrazole hybrid derivatives
Medicinal Chemistry Research (2023)
-
Conception, Synthesis and In silico Assessment of New Morpholine-Containing Compounds Against Human Legumain and Cholinesterase Enzymes
Chemistry Africa (2023)
-
Computationally repurposing drugs for breast cancer subtypes using a network-based approach
BMC Bioinformatics (2022)
-
Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking
Network Modeling Analysis in Health Informatics and Bioinformatics (2022)
-
A computationally affordable approach for accurate prediction of the binding affinity of JAK2 inhibitors
Journal of Molecular Modeling (2022)